NCT03866434View on ClinicalTrials.gov

Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 26, 2019

Primary Completion Date

April 10, 2019

Study Completion Date

April 10, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

SPD422

Participants will receive 1 mg of SPD422 (2\*0.5 mg) capsule orally on Day 1 and 8 in fasted state.

DRUG

Omeprazole

Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.

Trial Locations (1)

37920

New Orleans Center for Clinical Research, Knoxville

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT03866434 - Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants | Biotech Hunter | Biotech Hunter